Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder

Phase 3 Completed 514 enrolled Eli Lilly and Company Boehringer Ingelheim · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.

Timeline

Start: 2005-03
Primary completion: 2008-01
Completion: 2008-01

Publications

Perahia DG, Maina G, Thase ME, Spann ME, Wang F, Walker DJ, Detke MJ. Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009 May;70(5):706-16. doi: 10.4088/jcp.08m04756.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Duloxetine	Small molecule	60 mg	Oral
Subject	Duloxetine	Small molecule	120 mg	Oral

Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder

Summary

Timeline

Publications

Drugs

Indications